nicardipine has been researched along with Cerebrovascular Disorders in 23 studies
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This retrospective review compared nicardipine with clevidipine for hypertension in acute stroke patients from March 17, 2015 to December 23, 2016." | 7.88 | Comparison of Nicardipine with Clevidipine in the Management of Hypertension in Acute Cerebrovascular Diseases. ( Conklen, K; Deshpande, M; Ferrill, D; Jones, B; Rosenfeldt, Z; Siddiqui, FM, 2018) |
| "Nicardipine is a second generation dihydropyridine-type Ca2+ antagonist with high vascular selectivity and strong cerebral and coronary vasodilatory activity." | 6.39 | Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-related disorders. ( Amenta, F; Sabbatini, M; Strocchi, P, 1995) |
| " Controlling acute hypertension (HTN) by antihypertensive drugs such as clevidipine and nicardipine can be a highly efficient method of lowering the incidence of CVDs." | 5.41 | Comparison between clevidipine and nicardipine in cerebrovascular diseases: A systematic review and meta-analysis. ( Asgarzadeh, S; Azari Jafari, A; Azari Jafari, M; Godoy, DA; Mirmoeeni, S; Nazari, S; Seifi, A; Shah, M, 2023) |
| "Drug-induced gingival hyperplasia is usually associated with the administration of hydantoin in individuals with epilepsy." | 5.30 | [Nicardipine-induced gingival hyperplasia]. ( Pascual Pascual, SI; Pascual-Castroviejo, I, 1997) |
| "This retrospective review compared nicardipine with clevidipine for hypertension in acute stroke patients from March 17, 2015 to December 23, 2016." | 3.88 | Comparison of Nicardipine with Clevidipine in the Management of Hypertension in Acute Cerebrovascular Diseases. ( Conklen, K; Deshpande, M; Ferrill, D; Jones, B; Rosenfeldt, Z; Siddiqui, FM, 2018) |
| " DESIGN OF STUDIES: Mean cerebral circulation parameters were studied in chronic stroke patients with hypertension and treated acutely or chronically (2 weeks) with nicardipine or nifedipine retard." | 3.68 | Effects of dihydropyridines on cerebral blood vessels. ( Hashimoto, H; Kuriyama, Y; Nagatsuka, K; Omae, T; Sawada, T, 1993) |
| "Nicardipine is a dihydropyridine-type Ca(2+) channel blocker (CCB) with strong antihypertensive activity and with a peculiar cerebrovascular profile." | 2.45 | Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. ( Amenta, F; Lanari, A; Mignini, F; Silvestrelli, G; Tomassoni, D; Traini, E, 2009) |
| "Nicardipine is a dihydropyridine-type calcium channel blocker (CCB) with a peculiar cerebrovascular profile developed approximately 30 years ago." | 2.44 | Nicardipine: a hypotensive dihydropyridine-type calcium antagonist with a peculiar cerebrovascular profile. ( Amenta, F; Mignini, F; Tomassoni, D; Traini, E; Veglio, F, 2008) |
| "Nicardipine is a second generation dihydropyridine-type Ca2+ antagonist with high vascular selectivity and strong cerebral and coronary vasodilatory activity." | 2.39 | Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-related disorders. ( Amenta, F; Sabbatini, M; Strocchi, P, 1995) |
| "Nicardipine has no clinically significant negative inotropic effect." | 2.39 | Concomitant diseases in elderly hypertensives: the position of nicardipine. ( Zannad, F, 1996) |
| "Drug-induced gingival hyperplasia is usually associated with the administration of hydantoin in individuals with epilepsy." | 1.30 | [Nicardipine-induced gingival hyperplasia]. ( Pascual Pascual, SI; Pascual-Castroviejo, I, 1997) |
| "In the drug-untreated group, recurrence of stroke was repeated, deterioration and amelioration of neurological deficits (ND) were repeated, and histological examination and measurement of regional blood flow (rBF) using nonradioactive colored microspheres performed at the end of treatment revealed severe damages and significantly decreased rBF in brain and kidney, respectively." | 1.30 | Therapeutic effects of a calcium antagonist, lacidipine, on stroke-prone spontaneously hypertensive rats with cerebrovascular lesions. ( Funato, H; Uemura, A; Watanabe, M, 1999) |
| "Hypertension is a primary aggravating factor in cerebral infarction." | 1.29 | M1 receptors in blood pressure-controlled ischemic spontaneously hypertensive rats. ( Asanuma, M; Hirata, H; Kondo, Y; Ogawa, N; Tanaka, K, 1995) |
| " Chronic administration of YM-09730-5 (3 mg/kg) reduced the severity of glomerular lesions in the kidney and vasculitis in the mesenteric artery." | 1.28 | Antihypertensive and diuretic effects of YM-09730-5, a new calcium antagonist, in stroke-prone spontaneously hypertensive rats. ( Fujimoto, K; Inagaki, O; Kawashima, K; Oohata, H; Suzuki, T; Toda, H, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (17.39) | 18.7374 |
| 1990's | 13 (56.52) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Seifi, A | 1 |
| Azari Jafari, A | 1 |
| Mirmoeeni, S | 1 |
| Shah, M | 1 |
| Azari Jafari, M | 1 |
| Nazari, S | 1 |
| Asgarzadeh, S | 1 |
| Godoy, DA | 1 |
| Rosenfeldt, Z | 1 |
| Conklen, K | 1 |
| Jones, B | 1 |
| Ferrill, D | 1 |
| Deshpande, M | 1 |
| Siddiqui, FM | 1 |
| Amenta, F | 3 |
| Tomassoni, D | 2 |
| Traini, E | 2 |
| Mignini, F | 2 |
| Veglio, F | 1 |
| Lanari, A | 1 |
| Silvestrelli, G | 1 |
| Fletcher, JJ | 1 |
| Kramer, AH | 1 |
| Bleck, TP | 1 |
| Solenski, NJ | 1 |
| Samaniego, EA | 1 |
| Dabus, G | 1 |
| Generoso, GM | 1 |
| Tari-Capone, F | 1 |
| Fuentes, K | 1 |
| Linfante, I | 1 |
| Hirata, H | 1 |
| Asanuma, M | 1 |
| Tanaka, K | 1 |
| Kondo, Y | 1 |
| Ogawa, N | 1 |
| Sabbatini, M | 1 |
| Strocchi, P | 1 |
| Kuramoto, K | 1 |
| Ueda, M | 1 |
| Masui, M | 1 |
| Kawakami, M | 1 |
| Matsunaga, K | 1 |
| Gemba, T | 1 |
| Ninomiya, M | 1 |
| Nakano, A | 1 |
| Torii, M | 1 |
| Adachi, I | 1 |
| Ito, H | 1 |
| Kuriyama, Y | 1 |
| Hashimoto, H | 1 |
| Nagatsuka, K | 1 |
| Sawada, T | 1 |
| Omae, T | 1 |
| Brown, CM | 1 |
| Calder, C | 1 |
| Alps, BJ | 1 |
| Spedding, M | 1 |
| Zannad, F | 1 |
| Pascual-Castroviejo, I | 1 |
| Pascual Pascual, SI | 1 |
| Shinyama, H | 1 |
| Nagai, H | 1 |
| Kawamura, T | 1 |
| Narita, Y | 1 |
| Nakamura, N | 1 |
| Kagitani, Y | 1 |
| Funato, H | 1 |
| Watanabe, M | 1 |
| Uemura, A | 1 |
| Ribas Mundó, M | 1 |
| Lozano, R | 1 |
| Rosenbaum, D | 1 |
| Zabramski, J | 1 |
| Frey, J | 1 |
| Yatsu, F | 1 |
| Marler, J | 1 |
| Spetzler, R | 1 |
| Grotta, J | 1 |
| Kawashima, K | 1 |
| Toda, H | 1 |
| Oohata, H | 1 |
| Fujimoto, K | 1 |
| Suzuki, T | 1 |
| Inagaki, O | 1 |
| Puccinelli, F | 1 |
| Pieraccini, F | 1 |
| Tomei, GP | 1 |
| Gargiulo, L | 1 |
| Morimoto, S | 1 |
| Ohyama, T | 1 |
| Hisaki, K | 1 |
| Matsumura, Y | 1 |
| del Ser, T | 1 |
| Bermejo, F | 1 |
| Gomara, S | 1 |
| Calandre, L | 1 |
| Gascón Ramón, G | 1 |
6 reviews available for nicardipine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Comparison between clevidipine and nicardipine in cerebrovascular diseases: A systematic review and meta-analysis.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; | 2023 |
Nicardipine: a hypotensive dihydropyridine-type calcium antagonist with a peculiar cerebrovascular profile.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; Dement | 2008 |
Nicardipine use in cerebrovascular disease: a review of controlled clinical studies.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Disorders; Cognition; Cognition D | 2009 |
Postpartum cerebral angiopathy treated with intra-arterial nicardipine and intravenous immunoglobulin.
Topics: Adult; Cerebrovascular Disorders; Female; Humans; Immunoglobulins, Intravenous; Infusions, Intra-Art | 2013 |
Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-related disorders.
Topics: Aged; Animals; Brain; Brain Ischemia; Calcium Channels; Cerebrovascular Disorders; Humans; Hypertens | 1995 |
Concomitant diseases in elderly hypertensives: the position of nicardipine.
Topics: Aging; Calcium Channel Blockers; Cerebrovascular Disorders; Humans; Hypertension; Kidney Diseases; N | 1996 |
3 trials available for nicardipine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Treatment of elderly hypertensives in Japan: National Intervention Cooperative Study in Elderly Hypertensives. The National Intervention Cooperative Study Group.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; Female; Humans; Hyper | 1994 |
The influence of nicardipine in patients with high risk of stroke.
Topics: Aged; Aged, 80 and over; Cerebrovascular Disorders; Disease Susceptibility; Female; Humans; Male; Mi | 1990 |
Early treatment of ischemic stroke with a calcium antagonist.
Topics: Blood Pressure; Brain Ischemia; Cerebrovascular Disorders; Drug Evaluation; Feasibility Studies; Hum | 1991 |
14 other studies available for nicardipine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Comparison of Nicardipine with Clevidipine in the Management of Hypertension in Acute Cerebrovascular Diseases.
Topics: Acute Disease; Aged; Antihypertensive Agents; Cerebrovascular Disorders; Cross-Sectional Studies; Fe | 2018 |
Overlapping features of eclampsia and postpartum angiopathy.
Topics: Adult; Cerebrovascular Disorders; Eclampsia; Female; Headache; Humans; Methylprednisolone; Nicardipi | 2009 |
M1 receptors in blood pressure-controlled ischemic spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cerebrovascular Circulation; Cerebrovascular Disorders; Frontal Lobe; Hippo | 1995 |
Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 4th communication: prophylactic and therapeutic effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3- b]pyridine-5-carboxylate in stroke-prone spont
Topics: Animals; Behavior, Animal; Blood Pressure; Body Weight; Brain; Calcium Channel Blockers; Cerebrovasc | 1993 |
Effects of dihydropyridines on cerebral blood vessels.
Topics: Administration, Oral; Blood Pressure; Cerebral Infarction; Cerebrovascular Circulation; Cerebrovascu | 1993 |
The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Carotid Arteries; Cerebrovascular Disorders; Corp | 1993 |
[Nicardipine-induced gingival hyperplasia].
Topics: Calcium Channel Blockers; Cerebrovascular Disorders; Child; Gingival Hyperplasia; Humans; Male; Nica | 1997 |
Therapeutic effects of AE0047, a novel calcium antagonist, on progression of brain damage after stroke in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Brain; Calcium Channel Blockers; Cerebrovascular Disorders; Dihydropyridines; Hydralazine; | 1998 |
Therapeutic effects of a calcium antagonist, lacidipine, on stroke-prone spontaneously hypertensive rats with cerebrovascular lesions.
Topics: Animals; Blood Pressure; Body Weight; Brain; Calcium Channel Blockers; Cerebellum; Cerebrovascular D | 1999 |
Antihypertensive and diuretic effects of YM-09730-5, a new calcium antagonist, in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorder | 1991 |
[Arterial hypertension during the rehabilitation phase of cerebral stroke. Study with nicardipine].
Topics: Aged; Aged, 80 and over; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Middle Aged; | 1989 |
Effects of CV-4093, a new dihydropyridine calcium channel blocker, on renal hemodynamics and function in stroke-prone spontaneously hypertensive rats (SHRSP).
Topics: Animals; Body Weight; Calcium Channel Blockers; Cerebrovascular Disorders; Dihydropyridines; Hemodyn | 1989 |
[Does nicardipine improve chronic cerebrovascular insufficiency?].
Topics: Cerebrovascular Disorders; Humans; Nicardipine; Nifedipine; Vasodilator Agents | 1986 |
[Chronic cerebral vascular pathology].
Topics: Age Factors; Brain Diseases; Cerebrovascular Disorders; Diagnosis, Differential; Humans; Nicardipine | 1985 |